VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned an average rating of “Reduce” from the five analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $0.95.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st.

Hedge Funds Weigh In On VistaGen Therapeutics

Several large investors have recently modified their holdings of VTGN. AdvisorShares Investments LLC lifted its holdings in VistaGen Therapeutics by 10.8% during the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after buying an additional 26,922 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter worth $42,000. Renaissance Technologies LLC raised its stake in shares of VistaGen Therapeutics by 81.2% in the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after acquiring an additional 130,509 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in shares of VistaGen Therapeutics by 49.2% in the first quarter. ADAR1 Capital Management LLC now owns 751,141 shares of the company’s stock valued at $429,000 after acquiring an additional 247,566 shares in the last quarter. Finally, BlackRock Inc. purchased a new position in VistaGen Therapeutics in the second quarter valued at $78,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Price Performance

Shares of VistaGen Therapeutics stock opened at $0.29 on Friday. The stock’s 50 day simple moving average is $0.25 and its 200-day simple moving average is $0.45. The stock has a market cap of $13.09 million, a P/E ratio of -0.18 and a beta of 0.39. VistaGen Therapeutics has a 1-year low of $0.20 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, research analysts expect that VistaGen Therapeutics will post -1.45 EPS for the current fiscal year.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc (NASDAQ: VTGN), formerly known as VistaGen Therapeutics, is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The company’s research centers on neuroactive nasal spray medicines designed to act rapidly and potentially avoid some of the systemic side effects associated with conventional treatments.

Vistagen’s lead product candidate is fasedienol, also known as PH94B, an investigational nasal spray being developed for anxiety-related disorders, including social anxiety disorder.